Valdoltra Orthopaedic Hospital, Ankaran, Slovenia.
Institute for Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Cartilage. 2021 Dec;13(1_suppl):456S-463S. doi: 10.1177/1947603520904759. Epub 2020 Feb 6.
To evaluate the effect of a single intra-articular injection of local anesthetic (LA) lidocaine on the viability of articular cartilage in the intact or osteoarthritic (OA) human knees, and to measure the synovial postinjection concentration of lidocaine in the knee.
This study includes 3 interconnected experiments: (A) Synovial LA concentration measurement after a 2% lidocaine injection before knee arthroscopy in 10 patients by liquid chromatography-tandem mass spectrometry (LC-MS/MS). (B) Human osteochondral explants ( = 27) from intact knees procured at autopsies were incubated for different time intervals (30 minutes, 2 hours, 24 hours) with 2% lidocaine, 0.04% lidocaine (measured), or culture medium (control), and later evaluated for cell viability by LIVE/DEAD staining. (C) Ten out of 19 matched patients scheduled for knee replacement received a single intra-articular injection of 2% lidocaine approximately 30 minutes prior to the procedure; 9 patients served as control. Osteochondral samples with OA changes were harvested during surgery and analyzed for chondrocyte viability by LIVE/DEAD staining.
(A) The synovial LA concentration was significantly lower than the primary concentration injected: average 0.23 mg/mL (0.02%), highest measured 0.37 mg/mL (0.04%). (B) exposure to a reduced LA concentration had no significant influence on chondrocyte viability in intact cartilage explants (24-hour averages: control, 93%; 0.04% lidocaine, 92%; 2% lidocaine, 79%). (C) Viability of chondrocytes in OA knees was similar between 2% lidocaine injection (85%) and control (80%).
A single intra-articular knee injection of 2% lidocaine did not influence the chondrocyte viability neither in healthy nor in OA cartilage. A fast postinjection reduction of synovial LA concentration (more than 40 times) is the most likely protective mechanism.
评估单次关节内注射局部麻醉剂(LA)利多卡因对完整或骨关节炎(OA)人膝关节关节软骨活力的影响,并测量膝关节内注射后利多卡因的滑膜浓度。
本研究包括 3 个相互关联的实验:(A)通过液相色谱-串联质谱法(LC-MS/MS)测量 10 例膝关节镜检查前 2%利多卡因关节内注射后的滑膜 LA 浓度。(B)从尸检获得的完整膝关节的人软骨下骨样本(=27)用 2%利多卡因、0.04%利多卡因(测量)或培养基(对照)孵育不同时间间隔(30 分钟、2 小时、24 小时),并用 LIVE/DEAD 染色评估细胞活力。(C)19 例匹配的膝关节置换患者中有 10 例在手术前约 30 分钟接受单次关节内注射 2%利多卡因;9 例作为对照。在手术中采集有 OA 改变的骨软骨样本,并通过 LIVE/DEAD 染色分析软骨细胞活力。
(A)滑膜 LA 浓度明显低于注射的初始浓度:平均 0.23mg/mL(0.02%),最高测量值 0.37mg/mL(0.04%)。(B)暴露于降低的 LA 浓度对完整软骨样本中的软骨细胞活力没有显著影响(24 小时平均值:对照,93%;0.04%利多卡因,92%;2%利多卡因,79%)。(C)2%利多卡因注射(85%)和对照(80%)之间 OA 膝关节的软骨细胞活力相似。
单次关节内膝关节注射 2%利多卡因既不会影响健康软骨也不会影响 OA 软骨的软骨细胞活力。注射后滑膜 LA 浓度的快速降低(超过 40 倍)是最可能的保护机制。